ResMed
465 hedge funds and large institutions have $9.58B invested in ResMed in 2018 Q2 according to their latest regulatory filings, with 62 funds opening new positions, 172 increasing their positions, 150 reducing their positions, and 38 closing their positions.
63% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 38
15% more repeat investments, than reductions
Existing positions increased: 172 | Existing positions reduced: 150
8% more capital invested
Capital invested by funds: $8.89B → $9.58B (+$694M)
4% more funds holding
Funds holding: 445 → 465 (+20)
1.65% more ownership
Funds ownership: 63.18% → 64.84% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
48% less call options, than puts
Call options by funds: $11M | Put options by funds: $21M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Los Angeles Capital Management
Los Angeles,
California
|
+$41.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$39M |
| 3 |
JP Morgan Chase
New York
|
+$37.8M |
| 4 |
Morgan Stanley
New York
|
+$22.7M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$20.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$59.5M |
| 2 |
BlackRock
New York
|
-$23.6M |
| 3 |
Goldman Sachs
New York
|
-$21.5M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$16.4M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$12.1M |
RMD Hedge Fund Activity: Q2 2018 in Review
465 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q2 2018, worth a combined $9.58B — up 7.8% from $8.89B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new RMD positions and 38 closed out — a net gain of 24 holders — while 172 added to existing stakes and 150 trimmed.
The largest buyer was Los Angeles Capital Management, adding an estimated $41.2M. The largest seller was Guggenheim Capital, cutting an estimated $59.5M.
- 465 institutional investors held ResMed (RMD) as of Q2 2018, up from 445 in Q1 2018.
- Funds reported $9.58B of ResMed stock for Q2 2018, up 7.8% quarter-over-quarter.
- 62 funds opened new ResMed positions in Q2 2018 and 38 closed out, a net change of +24 holders.
- The largest ResMed buyer in Q2 2018 was Los Angeles Capital Management, an estimated $41.2M added.
- The largest ResMed seller in Q2 2018 was Guggenheim Capital, an estimated $59.5M sold.
Based on aggregated 13F filings for Q2 2018.